#AM25IMPACT

@onclive.bsky.social

11 months ago

Pamiparib Plus Surufatinib Shows Modest Activity in Platinum-Resistant Ovarian Cancer Pamiparib plus surufatinib showed signals of activity with a largely hematologic adverse effect profile in patients with PARP-pretreated, platinum-resistant ovarian cancer.

Pamiparib Plus Surufatinib Shows Modest Activity in Platinum-Resistant Ovarian Cancer
#SGOMtg #AM25IMPACT #SGO2025
www.onclive.com/view/pamipar...

0 0 0 0

OncLive

@onclive.bsky.social

11 months ago

Metformin With IUD Boosts Responses in EIN and Endometrial Cancer Patients with endometrial cancer had slightly higher CR rates with metformin plus a levonorgestrel-releasing IUD vs historical data with the IUD alone.

Metformin With IUD Boosts Responses in EIN and Endometrial Cancer
#SGOMtg #AM25IMPACT #SGO2025
www.onclive.com/view/metform...

0 0 0 0

Siteman Cancer Center

@sitemancenter.bsky.social

11 months ago

#SGOmtg: @washumedicine.bsky.social gynecologic oncologist and surgeon Lindsay Kuroki, MD, presents today. #SGOMtg #AM25IMPACT

Check out the conference details here: bit.ly/4ioTbE8

0 0 0 0

OncLive

@onclive.bsky.social

1 year ago

Updated MIRASOL Data Support Mirvetuximab Soravtansine as SOC for FRα+ Platinum-Resistant Ovarian Cancer Mirvetuximab soravtansine continued to showcase superior OS, PFS, ORR, & DOR benefits over chemotherapy in FRα-positive platinum-resistant ovarian cancer.

Updated MIRASOL Data Support Mirvetuximab Soravtansine as SOC for FRα+ Platinum-Resistant Ovarian Cancer #SGOMtg #AM25IMPACT #SGO2025 #ovca #gyncsm www.onclive.com/view/updated...

1 0 0 0

Siteman Cancer Center

@sitemancenter.bsky.social

1 year ago

#SGOmtg: @washumedicine.bsky.social gynecologic oncologist and surgeon Matthew A. Powell, MD, presents today. #SGOMtg #AM25IMPACT

Check out the conference details here: bit.ly/4ioTbE8

0 0 0 0

OncLive

@onclive.bsky.social

1 year ago

Zimberelimab Plus Lenvatinib Shows Activity in ICI-Pretreated Advanced Cervical Cancer The combination of zimberelimab and lenvatinib had antitumor activity and a manageable safety profile in pretreated advanced cervical cancer.

Zimberelimab Plus Lenvatinib Shows Activity in ICI-Pretreated Advanced Cervical Cancer #SGOMtg #AM25IMPACT #SGO2025 #oncology #gyncsm
www.onclive.com/view/zimbere...

0 0 0 0

OncLive

@onclive.bsky.social

1 year ago

Afuresertib Plus Paclitaxel Does Not Elicit Substantial Clinical Benefit in Platinum-Resistant Ovarian Cancer Afuresertib combined with paclitaxel did not elicit PFS or OS benefits vs paclitaxel alone in patients with unselected platinum-resistant ovarian cancer.

Afuresertib Plus Paclitaxel Does Not Elicit Substantial Clinical Benefit in Platinum-Resistant Ovarian Cancer #SGOMtg #AM25IMPACT #SGO2025 #gyncsm #oncology
www.onclive.com/view/afurese...

0 0 0 0

OncLive

@onclive.bsky.social

1 year ago

Olaparib After Durvalumab/Chemo Boosts PFS in Subgroups of pMMR Endometrial Cancer Olaparib maintenance following durvalumab plus chemotherapy improved PFS in different subgroups of pMMR endometrial cancer.

Olaparib After Durvalumab/Chemo Boosts PFS in Subgroups of pMMR Endometrial Cancer #SGOMtg #AM25IMPACT #SGO2025 www.onclive.com/view/olapari...

1 0 0 0

OncLive

@onclive.bsky.social

1 year ago

Pembrolizumab Plus Concurrent Chemoradiotherapy Improves OS, PFS2 in Advanced Cervical Cancer The addition of pembrolizumab to chemoradiotherapy prolonged survival and time to second progression in patients with locally advanced cervical cancer.

Pembrolizumab Plus Concurrent Chemoradiotherapy Improves OS, PFS2 in Advanced Cervical Cancer @uvahealth.bsky.social #SGOMtg #AM25IMPACT #SGO2025 #gyncsm www.onclive.com/view/pembrol...

0 0 0 0

OncLive

@onclive.bsky.social

1 year ago

Cadonilimab Plus Lenvatinib Proves Active in Platinum-Pretreated, Advanced Endometrial Cancer Cadonilimab plus lenvatinib showed promise as therapy for patients with advanced endometrial cancer and disease progression on prior platinum therapy.

Cadonilimab Plus Lenvatinib Proves Active in Platinum-Pretreated, Advanced Endometrial Cancer
#SGOMtg #AM25IMPACT #SGO2025
www.onclive.com/view/cadonil...

0 0 0 0

OncLive

@onclive.bsky.social

1 year ago

Nivolumab Yields High Clinical CR Rates Allowing for Surgery Omission in dMMR/MSI-H Endometrial Cancer Nivolumab elicited PR/CRs in all patients treated with resectable dMMR endometrial cancer and no patients experienced disease recurrence during follow-up.

Nivolumab Yields High Clinical CR Rates Allowing for Surgery Omission in dMMR/MSI-H Endometrial Cancer #SGOMtg #AM25IMPACT #SGO2025 #gyncsm www.onclive.com/view/nivolum...

1 0 0 0

OncLive

@onclive.bsky.social

1 year ago

Good morning Seattle! 🌆

☔ Rain or shine, we're ready to kick off our live coverage of #SGO2025! From expert-led sessions to cutting-edge research, we’ll be sharing all the latest updates in gynecologic oncology. You won't want to miss it!

#SGOMtg #AM25IMPACT #gynsm

1 0 0 0

Siteman Cancer Center

@sitemancenter.bsky.social

1 year ago

The Society of Gynecologic Oncology’s Annual Meeting on Women’s Cancer takes place this weekend, featuring presentations by @washumedicine.bsky.social physicians Matthew Powell, MD, and Lindsay Kuroki, MD. #SGOMtg #AM25IMPACT #SGO2025

Learn more: bit.ly/4hsHDOR

0 0 0 0

researchmatters.bsky.social

@researchmatters.bsky.social

1 year ago

Who will be at #SGOMtg? I'm speaking at the Patient Advocate Panel on March 14 about how I've become an accidental advocate (but a committed one!)
#AM25IMPACT

0 0 0 0

Posts tagged #AM25IMPACT